Rheumatoid Arthritis Clinical Trial
Official title:
Post-market Registry Study on the Physica System Total Knee Replacement
NCT number | NCT03048201 |
Other study ID # | K-11 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 24, 2017 |
Est. completion date | March 2030 |
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | March 2030 |
Est. primary completion date | March 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. Males and females of any race requiring a total knee replacement and suitable for the use of one of the configurations of the Physica system 2. Age> 22 (skeletally mature) 3. Patients who are suffering from non-inflammatory degenerative joint disease (NIDJD): including knee osteoarthritis, post-traumatic knee arthritis; or patients who are suffering from inflammatory arthritis; or patients that need correction of a functional deformity 4. Suitable candidates for TKR who have undamaged and functional collateral ligaments 5. Suitable candidates for TKR with Physica KR, CR, who have an undamaged and functional posterior cruciate ligament; or Physica LMC with or without a functioning posterior cruciate ligament or Physica PS with an absent or not-functioning posterior cruciate ligament and/or severe antero-posterior instability of the knee joint 6. Patients who understand the conditions of the study and are willing and able to comply with the prescribed rehabilitation and to perform all scheduled follow-up visits 7. Patients who have signed the Ethics Committee/IRB approved study-specific Informed Consent Form prior to the surgery Exclusion Criteria: 1. Patients with severe instability of the knee joint secondary to the absence of collateral ligament integrity and/or function 2. Patients with active or any suspected infection (on the affected knee or systemic) 3. Previous partial knee replacement (unicompartimental, bicompartimental or patellofemoral joint replacement), patellectomy, high tibial osteotomy 4. Patients with significant bone loss on femoral or tibial joint side 5. Current treatment for malignant and/or life-threatening non-malignant disorders 6. Patients with known incompatibility or allergy to the product materials, and/or metal hypersensitivity to implant materials 7. Vascular insufficiency of lower limbs severe enough to interfere with the study evaluation 8. Patients with bone stock compromised by disease, infection or prior implantation that cannot provide adequate support and/or fixation to the prosthesis 9. Patients with systemic or metabolic disorders leading to progressive bone deterioration which may impair fixation and stability of the implant 10. Any concomitant disease and dependence that might affect the performance of the implanted prosthesis 11. Any clinically significant pathology based on clinical history that the Investigator feels may affect the study evaluation (e.g. primary osteoporosis with significant bone loss, haemophilic disease, septicaemia, persistent acute or chronic osteomyelitis) 12. Patients who have significant neurological or musculoskeletal disorders or disease that may adversely affect gait and compromise functional recovery and evaluation 13. Patients who have neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device 14. Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint 15. Any psychiatric illness that would prevent comprehension of the details and nature of the study 16. Patients currently participating in any other surgical intervention studies or pain management studies 17. Female patients who are pregnant, nursing, or planning a pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Rush Castle Orthopaedics | Aurora | Illinois |
United States | The Orthopedics Clinic | Daytona Beach | Florida |
United States | Joint Reconstructive Specialist | Oklahoma City | Oklahoma |
United States | Eisenhower Desert Orthopedics Center - Harry and Diane Rinker Bldg | Rancho Mirage | California |
United States | Syracuse Orthopedic Specialists | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
Limacorporate S.p.a |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Implant Survivorship | The primary endpoint is the definition of the implant survivorship of the study device to 10 years after the total knee replacement surgery. | 10 years | |
Secondary | American Knee Society Score (KSS) 2011 | Clinical performance assessment measured by overall pain and functionality from baseline to 10-year follow-up | 10 years | |
Secondary | Patient-Reported Outcome Measures (PROMs) | Patient-Reported Outcome Measures (PROMs) including patient satisfaction achievement from baseline to 10-year follow-up | 10 years | |
Secondary | Radiographic Evaluation | • Radiographic implant evaluation and stability assessment from baseline to 10-year follow-up | 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |